Dr. Charles J. Ryan of the University of California, San Francisco, joins Dr. Walter M. Stadler, associate editor of The Oncology Report, in a discussion of leading prostate cancer research at the 2012 annual meeting of the American Society of Clinical Oncology.
Topics include the pivotal abiraterone trial results presented by Dr. Ryan, novel androgen inhibitors, the role of prednisone, and the controversial conclusions of the largest and longest study comparing intermittent with continuous androgen deprivation therapy.